Clarius Mobile Health soon to offer handheld ultrasound compatible with iOS, Android

Clarius Mobile Health's wireless, handheld ultrasound scanner has a mobile application for iOA and Android smart devices. 

"Physicians have been asking for a portable ultrasound system that works with their iPhone for some time," said Laurent Pelissier, chairman and CEO of Clarius Mobile Health, in a release. "The challenge has been to make an affordable device that is small enough to carry around and that also produces great images. I'm happy to say we've succeeded in creating a product that will enable more clinicians to use ultrasound anywhere to improve patient care. It's as easy to use as a mobile phone camera."

With automated adjustments and an intuitive interface, the personal ultrasound device is designed to be carried around for quick exams and to guide procedures such as nerve blocks and targeted injections, according to the company.

Pending regulatory clearance from the FDA, CE and Health Canada, Clarius Mobile Health will offer several mobile scanners for the price of a single traditional compact system.

Beth Walsh,

Editor

Editor Beth earned a bachelor’s degree in journalism and master’s in health communication. She has worked in hospital, academic and publishing settings over the past 20 years. Beth joined TriMed in 2005, as editor of CMIO and Clinical Innovation + Technology. When not covering all things related to health IT, she spends time with her husband and three children.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.